Drugs / TRK-950
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03872947 | Apr 2019 → Jul 2026 | cholangiocarcinoma, colorectal cancer, fallopian tube cancer, gastric cancer +5 | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 1 | NCT02990481 | Mar 2017 → Sep 2019 | cholangiocarcinoma, colon carcinoma | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05423262 | Jul 2022 → Mar 2028 expected | cancer, melanoma | Toray Industries, Inc | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06038578 | Oct 2023 → Oct 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Toray Industries, Inc | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-08-06 | Toray Industries, Inc | 【注意喚起】がん抗体医薬「TRK-950」の名称等の不正使用について toray.com ↗ |
| 2025-08-06 | Toray Industries, Inc | 【Notice】Toray Warns Companies to Cease Unauthorized Use of its Trade Name and TRK-950 Antibody Name toray.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRK-950 | “We generated a therapeutic humanized anti-CAPRIN-1 antibody (TRK-950), which strongly and specifically binds to various cancer cells and shows antitumor effects via engagement...” PMID 37082579 ↗ Apr 2023 |
| Known as | Monoclonal antibody trk-950 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594360 ↗ |
| Modality | Monoclonal antibody | “therapeutic humanized anti-CAPRIN-1 antibody” PMID 37082579 ↗ Apr 2023 |
| Route | Intravenous | “Intravenously over 60 minutes” NCT02990481 ↗ |
| Target | CAPRIN1 | “anti-CAPRIN-1 antibody” PMID 37082579 ↗ Apr 2023 |